Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Selective inhibition of yeast regulons by daunorubicin

ABSTRACT: The antitumor drug daunorubicin exerts some of its cytotoxic effects by binding to DNA and inhibiting the transcription of different genes. We analysed this effect in vivo transcriptome level using the budding yeast Saccharomyces cerevisiae as a model and sublethal concentrations of the drug to minimise general toxic effects. The effects of daunorubicin treatment on the yeast transcriptome are consistent with a model in which this drug impairs binding of different transcription factors by competing for their DNA binding sequences, therefore limiting their effectiveness and affecting the corresponding regulatory networks. This proposed mechanism might have broad therapeutic implications against cancer cells growing under hypoxic conditions. Keywords: Time course experiment (treated versus non-treated)

ORGANISM(S): Saccharomyces cerevisiae

PROVIDER: GSE19351 | GEO | 2009/12/08

SECONDARY ACCESSION(S): PRJNA121729

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Selective inhibition of yeast regulons by daunorubicin

Project description:The antitumor drug daunorubicin exerts some of its cytotoxic effects by binding to DNA and inhibiting the transcription of different genes. We analysed this effect in vivo transcriptome level using the budding yeast Saccharomyces cerevisiae as a model and sublethal concentrations of the drug to minimise general toxic effects. The effects of daunorubicin treatment on the yeast transcriptome are consistent with a model in which this drug impairs binding of different transcription factors by competing for their DNA binding sequences, therefore limiting their effectiveness and affecting the corresponding regulatory networks. This proposed mechanism might have broad therapeutic implications against cancer cells growing under hypoxic conditions. Keywords: Time course experiment (treated versus non-treated) Treatment with a single concentration of daunorubicin (DNR, 12 mM, IC40) for 1 or 4 hours. Three biological replicates for each sampling time (0, 1 and 4h). Untreated cultures were used as controls.

2010-05-18 | E-GEOD-19351 | biostudies-arrayexpress

RNA-Seq analysis of HL-60 AML cells resistant to daunorubicin or cytarabine

Project description:The Acute Myeloid Leukemia cell line HL-60 was rendered resistant to daunorubicin (DNR) or cytarabine (Ara-C) by continuous exposure to the drug up to concentrations of 30nM for DNR and 100nM for Ara-C. Transcriptomic analysis were then performed by RNA-Seq to compare the cell lines

2022-01-08 | GSE193094 | GEO

Effect daunorubicin on the binding of the cohesin subunit Rad21 in HCT116 cells [ChIP-seq]

Project description:We used ChIP-seq to measure the binding of the cohesin subunit Rad21 in response to daunorubicin treatment in HCT116 cells

2016-09-30 | GSE86191 | GEO

Gene expression signatures in ex vivo Cytarabine (Ara-C) and Daunorubicin (Dnr) sensitive AML samples

Project description:Wide inter-individual variation in terms of outcome and toxic side effects of treatment exist among patients with AML receiving chemotherapy with cytarabine (Ara-C) and daunorubicin (Dnr). Drug resistance and relapse are considered major causes of treatment failure. Gene expression profiling was undertaken to address possible mechanisms of Ara-C/Dnr resistance. Based on ex vivo Ara-C cytotoxicity at diagnosis, Ara-C sensitive (IC50 <3uM AraC) and Dnr sensitive samples (IC50 < 0.5 uM) (5 samples each) were included for microarray analysis. These were compared with the samples which were drug resistant ex vivo at diagnosis. Our microarray experiment resulted in indentifying differentially expressed genes under ex vivo Ara-C sensitive as well as Dnr sensitive samples compared to ex vivo Drug resistant samples.

2016-01-02 | GSE52919 | GEO

Gene expression signatures in ex vivo Cytarabine (Ara-C) and Daunorubicin (Dnr) sensitive AML samples

2016-07-04 | E-GEOD-52919 | biostudies-arrayexpress

Effect daunorubicin treatment on the transcriptome of HCT116 cells [RNA-seq]

Project description:We used RNA-seq to measure the transcriptome of HCT116 in response to the DNA damaging agent daunorubicin

2016-09-30 | GSE86190 | GEO

Transcription profiling of human primary ALL cells (B-lineage) sensitive to daunorubicin by the MTT in vitro sensitivity assay

Project description:primary ALL cells (B-lineage) sensitive to daunorubicin by the MTT in vitro sensitivity assay

2008-06-15 | E-GEOD-659 | biostudies-arrayexpress

Transcription profiling of human primary ALL cells (B- and T-lineage) resistant to daunorubicin by the MTT in vitro sensitivity assay

Project description:primary ALL cells (B- and T-lineage) resistant to daunorubicin by the MTT in vitro sensitivity assay

2008-06-14 | E-GEOD-651 | biostudies-arrayexpress